Aligos Therapeutics, Inc.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2021 | — | $184.7M | $186.8M |
| FY2022 | — | $103.9M | $81.3M |
| FY2023 | — | $92.1M | $135.7M |
| FY2024 | — | $-29.0M | $37.0M |
| FY2025 | — | $53.5M | $18.3M |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2021 | — | $184.7M | $186.8M |
| FY2022 | — | $103.9M | $81.3M |
| FY2023 | — | $92.1M | $135.7M |
| FY2024 | — | $-29.0M | $37.0M |
| FY2025 | — | $53.5M | $18.3M |